.
MergerLinks Header Logo

Announced

Completed

Inotiv completed the acquisition of Envigo for $545m.

Financials

Edit Data
Transaction Value£396m
Consideration TypeCash, Ordinary Shares
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Domestic

Single Bidder

United States

Friendly

Private

Majority

research services

Health Care Services

Acquisition

medical services

Completed

testing inspection and certification

Synopsis

Edit

Inotiv, a contract research organization, completed the acquisition of Envigo, a global provider of research models and services, for $545m. "The combination of Inotiv and Envigo allows drug developers to work with one organization for the entirety of discovery and nonclinical development, while getting the same highly personalized service that characterizes both companies. The combined company has excellent growth opportunities, and we plan to continue to make investments for organic growth while selectively pursuing strategic acquisitions. Envigo has a long history and deep experience with supply of critical research models, which will be integrated with Inotiv’s range of nonclinical and analytical services. This provides clients with a unique, full-spectrum discovery-to-approval solution to meet the increasing growth and innovation in biopharma and demand for specialty and disease-specific models," Robert Leasure, Inotiv President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US